Advertisement

Management of Hepatobiliary and Pancreatic Malignancies

  • Ashwin deSouzaEmail author
Chapter
  • 585 Downloads
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)

Abstract

Surgery plays an integral role and perhaps offers the only curative option in the management of hepatobiliary and pancreatic malignancies. Chemotherapy and radiation, either in the neoadjuvant or adjuvant setting, have further complemented the outcomes of radical surgery and play an important role in palliation. This chapter presents the principles of management of hepatocellular carcinoma (HCC), cancers of the gall bladder and biliary tract and pancreatic cancer.

References

  1. 1.
    Bruix J. Treatment of hepatocellular carcinoma. Hepatology. 1997;25:259.CrossRefPubMedGoogle Scholar
  2. 2.
    Vauthey JN, Klimstra D, Franceschi D, et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg. 1995;169:28.CrossRefPubMedGoogle Scholar
  3. 3.
    Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996;111:1018.CrossRefPubMedGoogle Scholar
  4. 4.
    Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer ≤2cm: results from two western centers. Hepatology. 2013;57:1426.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patient with cirrhosis. N Engl J Med. 1996;334:693.CrossRefPubMedGoogle Scholar
  6. 6.
    Lo CN, Ngan H, Tsa WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164.CrossRefPubMedGoogle Scholar
  7. 7.
    Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002;359:1734.CrossRefPubMedGoogle Scholar
  8. 8.
    Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolisation for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52.CrossRefPubMedGoogle Scholar
  9. 9.
    Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.CrossRefPubMedGoogle Scholar
  10. 10.
    Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.CrossRefGoogle Scholar
  11. 11.
    Jayaraman S, Jarnagin WR. Management of gall bladder cancer. Gastroenterol Clin North Am. 2010;39:331.CrossRefPubMedGoogle Scholar
  12. 12.
    Shirai Y, Yoshida K, Tsukada K, et al. Early carcinoma of the gall bladder. Eur J Surg. 1992;158:545.PubMedGoogle Scholar
  13. 13.
    Wakai T, Shirai Y, Yokoyama N, et al. Early gall bladder carcinoma does not warrant radical resection. Br J Surg. 2001;88:675.CrossRefPubMedGoogle Scholar
  14. 14.
    You DD, Lee HG, Paik Ky, et al. What is an adequate extent of resection for T1 gall bladder cancers? Ann Surg 2008;247:835.Google Scholar
  15. 15.
    Matsumoto Y, Fujii H, Aoyama H, et al. Surgical treatment of primary carcinoma of the gall bladder based on the histologic analysis of 48 surgical specimens. Am J Surg. 1992;163:239.CrossRefPubMedGoogle Scholar
  16. 16.
    Shimada H, Endo I, Togo S, et al. The role of lymph node dissection in the treatment of gall bladder carcinoma. Cancer. 1997;79:892.CrossRefPubMedGoogle Scholar
  17. 17.
    Nimura Y, Hayakawa N, Kamiya J, et al. Hepatopancreatoduodenectomy for advanced carcinoma of the biliary tract. Hepatogastroenterology. 1991;38:170.PubMedGoogle Scholar
  18. 18.
    Nakamura S, Suzuki S, Konno H, et al. Outcome of extensive surgery for TNM stage IV carcinoma of the gall bladder. Hepatogastroenterology. 1999;46:2138.PubMedGoogle Scholar
  19. 19.
    Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar and distal tumours. Ann Surg. 1996;224:463.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lim JH, Choi GH, Choi SH, et al. Liver resection for Bismuth type I and type II hilar cholangiocarcinoma. World J Surg. 2013;37:829.CrossRefPubMedGoogle Scholar
  21. 21.
    Tan JW, Hu BS, Chu YJ et al. one-stage resection for Bismuth type IV hilar cholangiocarcinoma with high hilar resection and parenchyma-preserving strategies: a cohort study. World J Surg 2013;37:614.Google Scholar
  22. 22.
    Hemming AW, Mekeel K, Khanna A, et al. Portal vein resection in management of hilar cholangiocarcinoma. J Am Coll Surg. 2011;212:604.CrossRefPubMedGoogle Scholar
  23. 23.
    Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0890: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gall bladder carcinoma. J Clin Oncol. 2015;33:2617.CrossRefPubMedGoogle Scholar
  24. 24.
    Diener MK, Knaebel HP, Heukaufer C, et al. A systematic review and meta-analysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical treatment of periampullary and pancreatic carcinoma. Ann Surg. 2007;245:187.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Van de Gaag NA, Rauws EA, van Eijck CH, et al. Preoperative biliary drainage for cancer of the head of pancreas. N Engl J Med. 2010;362:129.CrossRefGoogle Scholar
  26. 26.
    Barugola G, Partelli S, Crippa S, et al. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg. 2012;203:132.CrossRefPubMedGoogle Scholar
  27. 27.
    McClaine RJ, lowry AM, Sussman JJ, et al. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB (Oxford) 2010;12:73.Google Scholar
  28. 28.
    Seufferlein T, Bachet JB, Van Cutsem E, et al. Pancreatic adenocarcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii33.CrossRefPubMedGoogle Scholar
  29. 29.
    Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guidelines. J Clin Oncol. 2016;34:2541.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Department of Gastrointestinal and HPB SurgeryTata Memorial CentreMumbaiIndia

Personalised recommendations